Excepted Cytodyn's DSMB did request another interim review at 75%.
I quote Nader Pourhassan (Cytodyn's CEO) 's October 20th conference call, they requested this new interim to perform a "sample size reassessment". Which is precisely what the DSMB needs to do if they doubt that they will have enough patients to detect any hypothetical treatment effect In such case they want another opportunity to reestimate where they are with more data, before the clinical trial disbands.
And if they see a risk that the data may still not be sufficient to make a better guess, they also try to gather more signals, by extending the death measurement time frame. That's exactly what they also did, asking to be able to measure mortality at 42 days (was 28 days previously) after initial treatment.
It is Nader who has refused to follow their recommendation, not the DSMB.
Market Data 
Markets 
AI
